WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

A Series A, B and an IPO; Cabaletta reports CAR-T results

Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises $122 million; and more

Raccontata dastatnews.comendpoints.news

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
endpoints.newsStai leggendo1 mesi fa

A Series A, B and an IPO; Cabaletta reports CAR-T results

Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises $122 million; and more

originale
statnews.com1 mesi fa

CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. 

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 14 maggio 2026·statnews.com

    CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

    CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. 

  2. giovedì 14 maggio 2026·endpoints.news

    A Series A, B and an IPO; Cabaletta reports CAR-T results

    Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises $122 million; and more